List Title | APhA DrugInfoLine

Focus on Diabetes Care

SORT BY: Most Recent Most Viewed

June 20, 2017

Fracture risk increased with pioglitazone

READ

PREVIEW
Use of pioglitazone, an oral thiazolidinedione antihyperglycemic agent, was associated with an increased risk of bone fractures in insulin-resistant, nondiabetic patients with a recent history of...
May 16, 2017

New trial supports use of lixisenatide in older, nonfrail adults with type 2 diabetes

READ

PREVIEW
Use of once-daily lixisenatide (Adlyxin—Sanofi-Aventis) in older, nonfrail patients whose type 2 diabetes (T2D) was not controlled on their current antidiabetic regimen resulted in improvements in...
March 27, 2017

New guidance on diabetic neuropathy

READ

PREVIEW
A new position statement by the American Diabetes Association (ADA) focuses on prevention, screening, and management of several diabetic neuropathies, including distal symmetric polyneuropathy (...
March 7, 2017

Updated guideline released on use of oral medications to manage type 2 diabetes

READ

PREVIEW
Metformin remains the initial treatment of choice for patients with type 2 diabetes, and if a second agent is needed, clinicians should consider adding a sulfonylurea, a thiazolidinedione, a...
December 27, 2016

Fewer CV events observed in patients with diabetes receiving intensive glycemic therapy plus beta blockers

READ

PREVIEW
Intensive glycemic therapy in patients with type 2 diabetes who were also receiving beta blockers was associated with a reduction in the risk of cardiovascular (CV) events compared with those on...

Pages

Medication Monitor

RSS Follow Medication Monitor on Twitter Follow APhA Druginfoline on Twitter

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.